AARTIDRUGS:NSE-Aarti Drugs Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 468.75

Change

+4.85 (+1.05)%

Market Cap

INR 43.55B

Volume

0.13M

Avg Analyst Target

N/A

Avg User Target

INR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AARTIDRUGS Stock Forecast & Price:
Based on the Aarti Drugs Limited stock forecasts from 0 analysts, the average analyst target price for Aarti Drugs Limited is not available over the next 12 months. Aarti Drugs Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aarti Drugs Limited is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Aarti Drugs Limited’s stock price was INR 468.75. Aarti Drugs Limited’s stock price has changed by +0.32% over the past week, +8.63% over the past month and -22.81% over the last year.

About Aarti Drugs Limited (AARTIDRUGS:NSE)

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungal ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+17.95 (+1.93%)

INR2,256.45B 58.05 28.62
DIVISLAB:NSE Divi's Laboratories Limited

+11.55 (+0.31%)

INR982.22B 31.09 23.64
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-25.00 (-0.57%)

INR718.64B 24.22 12.88
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+14.05 (+0.91%)

INR525.13B 65.61 24.96
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+4.05 (+1.06%)

INR392.29B 18.28 10.34
ALKEM:NSE Alkem Laboratories Limited

+17.35 (+0.53%)

INR390.28B 30.20 22.56
AUROPHARMA:NSE Aurobindo Pharma Limited

+0.90 (+0.18%)

INR308.18B 12.48 6.68
LUPIN:NSE Lupin Limited

+25.05 (+3.83%)

INR304.13B 25.10 -87.34
LAURUSLABS:NSE Laurus Labs Limited

+3.55 (+0.70%)

INR274.16B 32.84 19.79
IPCALAB:NSE IPCA Laboratories Limited

+5.60 (+0.62%)

INR225.42B 31.93 17.59

ETFs Containing AARTIDRUGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.98% 63% D 37% F
Dividend Return 0.18% 10% F 9% F
Total Return -13.79% 65% D 36% F
Trailing 12 Months  
Capital Gain -22.46% 49% F 21% F
Dividend Return 0.17% 5% F 7% F
Total Return -22.29% 49% F 20% F
Trailing 5 Years  
Capital Gain -10.12% 29% F 38% F
Dividend Return 1.05% 15% F 13% F
Total Return -9.07% 29% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 18.03% 45% F 53% F
Dividend Return 0.18% 24% F 16% F
Total Return 18.21% 44% F 52% F
Risk Return Profile  
Volatility (Standard Deviation) 108.97% 17% F 16% F
Risk Adjusted Return 16.71% 23% F 33% F
Market Capitalization 43.55B 66% D 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.78 53% F 46% F
Price/Book Ratio 3.95 33% F 30% F
Price / Cash Flow Ratio 62.53 16% F 12% F
EV/EBITDA 14.10 45% F 38% F
Management Effectiveness  
Return on Equity 21.03% 81% B- 78% C+
Return on Invested Capital 15.35% 70% C- 77% C+
Return on Assets 9.07% 74% C 79% C+
Debt to Equity Ratio 13.36% 43% F 48% F
Technical Ratios  
Dividend Yield 0.21% 7% F 12% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.20 27% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.